Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, ...

RWD and RWE are reshaping the design of clinical trials, making them smarter, faster, and more efficient. Read more here: ...

The FDA draft guidance recommends MRD and CR as endpoints for accelerated drug approval in multiple myeloma, emphasizing ...

DARE to PLAY™ represents the first and only evidence-backed sildenafil cream formulation for women. Its commercial availability through a 503B outsourcing facility will mark the first time a topical ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

Most return-to-office mandates aren’t solving a collaboration problem. They’re solving an assessment problem that physical ...

The design of the tower’s stainless steel panels is a direct result of Gehry’s love of Toronto’s northern light and how it changes during the four seasons ...

This engagement begins as a defined pilot, with a clear path to expand into a multi-study commercial relationship based on results. For Lunai, this is the kind of near-term work that can translate ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

By Dr. Sanchari Sinha Dutta, Ph.D. A randomized trial suggests that avoiding coffee after cardioversion may not help, and that modest caffeine intake may actually be associated with fewer atrial ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...